Evaluation of JAK2V617F CH in non-MPN populations. Since 2007, more than 350 000 individuals from general population studies have been examined for JAK2V617F CH. Published reports of 353 707 unique individuals, JAK2V617F CH prevalence, and clinical associations are listed on the timeline. Significant differences in blood counts, cancer risk, and thrombosis risk between JAK2V617F CH populations and controls are indicated in red.